Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW; ACTG A5086 Study Team.

J Infect Dis. 2006 Nov 1;194(9):1309-18. Epub 2006 Sep 22.

PMID:
17041858
2.

Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.

Lawrence J, Hullsiek KH, Thackeray LM, Abrams DI, Crane LR, Mayers DL, Jones MC, Saldanha JM, Schmetter BS, Baxter JD.

J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):169-78.

PMID:
16951642
3.

A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).

Walmsley SL, Thorne A, Loutfy MR, LaPierre N, MacLeod J, Harrigan R, Trottier B, Conway B, Hay JR, Singer J, Zarowny D.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25.

PMID:
17468667
4.

A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.

Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, Vargas MB, Jahed NC, Jacobson JM, Myers LS, Schmitz JL, Winters M, Tebas P; A5102 Study Team of the AIDS Clinical Trials Group.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):140-8.

PMID:
16760795
5.

[Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].

Rey D, Schmitt MP, Hess-Kempf G, Krantz V, Partisani M, Bernard-Henry C, Lang JM.

Pathol Biol (Paris). 2001 Sep;49(7):559-66. French.

PMID:
11642019
6.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.

Clin Infect Dis. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.

PMID:
15714420
7.

Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.

Montroni M, Monforte AD.

Scand J Infect Dis Suppl. 2003;106:79-81. Review.

PMID:
15000591
8.

HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.

Izopet J, Marchou B, Charreau I, Sauné K, Tangre P, Molina JM, Aboulker JP; Window (ANRS 106) Study Team.

Antivir Ther. 2008;13(4):537-45.

PMID:
18672532
9.

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, Díaz M, Marfil S, Negredo E, García-Prado J, Tural C, Sirera G, Clotet B.

J Infect Dis. 2003 Oct 1;188(7):977-85. Epub 2003 Sep 23.

PMID:
14513417
10.

Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.

Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte Ad, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):39-47.

PMID:
17972364
11.

The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB; AIDS Clinical Trials Group 328 Study Team.

Arch Intern Med. 2007 Mar 26;167(6):597-605.

PMID:
17389292
12.
13.

The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).

Bloch MT, Smith DE, Quan D, Kaldor JM, Zaunders JJ, Petoumenos K, Irvine K, Law M, Grey P, Finlayson RJ, McFarlane R, Kelleher AD, Carr A, Cooper DA.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):192-202.

PMID:
16688094
14.

Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.

Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, Weber R, Hirschel B, Kostrikis LG, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2003 Nov 15;188(10):1433-43. Epub 2003 Nov 3.

PMID:
14624368
15.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
16.

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD; 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS.

N Engl J Med. 2003 Aug 28;349(9):837-46.

17.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

PMID:
19210162
18.

Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).

Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F, Aboulker JP; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 119 Interstart Study Team.

J Infect Dis. 2009 Jul 15;200(2):206-15. doi: 10.1086/599989.

PMID:
19508157
19.

Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.

Gandhi T, Nagappan V, Cinti S, Wei W, Kazanjian P.

Clin Infect Dis. 2007 Oct 15;45(8):1085-92. Epub 2007 Sep 14.

PMID:
17879930
20.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244

Supplemental Content

Support Center